Fragile sites and neuroblastoma: Fragile site at 1p13.1 and other points on lymphocyte chromosomes from patients and family members

Rudolph, Bärbel; Harbott, Jochen; Lampert, F.

doi:10.1016/0165-4608(88)90015-5

Cited by 16 publications

(6 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the variant allele for the rs2145418 marker and the overrepresented (14)(15)(16)(17). The single-nucleotide polymorphisms analyzed in this study were selected as genetic markers for susceptibility loci.…”

Section: Discussionmentioning

confidence: 99%

“…In a previous study, we have reported that the chromosome 1p12-13is related to thyroid cancer susceptibility (13). Several studies also indicate that this region undergoes many aberrations in different types of cancer (14)(15)(16)(17), which would suggest a certain role in cancer incidence. Here, we report the localization of susceptibility factors to thyroid cancer in this region.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Strong Association of Chromosome 1p12 Loci with Thyroid Cancer Susceptibility

Baida

Akdi

González-Flores

et al. 2008

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Several genes directly related to thyroid cancer development have been described; nevertheless, the genetic pathways of this tumorigenesis process are unknown. Together with environmental factors, susceptibility genes could have an important role in thyroid cancer. Our previous studies suggest that the chromosome 1p12-13 is related to thyroid cancer incidence. Here, we extend the analysis with a case-control association study in a Spanish population. Thus, six singlenucleotide polymorphisms were genotyped, covering 2.4 Mb of the 1p12-13 region. A statistically significant association between thyroid cancer incidence and the rs2145418 and rs4658973 polymorphisms was found (P < 0.0001). No association was detected for the other four polymorphisms studied. The rs2145418 marker showed a significant odds ratio of 5.0 [95% confidence interval (95% CI), 2.85-8.83] and 9.2 (95% CI, 4.50-21.6) for heterozygous and homozygous G-variant alleles, respectively. For rs4658973, the odds ratios were 0.40 (95% CI, 0.26-0.62) and 0.07 (95% CI, 0.03-0.18) for heterozygous and homozygous G-variant alleles, respectively. These markers map into the 1p12 region, and no linkage disequilibrium was found between them, indicating an independent relation of these polymorphisms with thyroid cancer susceptibility. Our data provide evidence of a strong association of the chromosome 1p12 with thyroid cancer risk, and it is the first study describing susceptibility loci for thyroid cancer in this region. (Cancer Epidemiol Biomarkers Prev 2008;17(6):1499 -504)

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Strong Association of Chromosome 1p12 Loci with Thyroid Cancer Susceptibility

Baida

Akdi

González-Flores

et al. 2008

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…Experiments with aphadicolin for the induction of fragile sites fra(1)(p 13.1) were not performed (Yunis and Soreng 1984;Rudolph et al 1988;Vernole et al 1988).…”

Section: Discussionmentioning

confidence: 99%

Cytogenetic and molecular characterization of a newly established neuroblastoma cell line LS

et al. 1991

View full text Add to dashboard Cite

A new human neuroblastoma cell line (LS) that originated from an abdominal tumor of a 16-month-old girl is presented; it was classified, according to Evans, as being stage III. Morphological (dense-core particles) and biochemical characteristics (dopamine-beta-hydroxylase, acetylcholinesterase, neuron-specific-enolase) confirmed the diagnosis. In addition to a slightly variable modal chromosome number of 48 or 49 (because of marker-chromosomes and autosomal trisomies), cytogenetic analysis revealed two constantly appearing chromosomes with homogeneously stained regions (HSR's). The karyotype remained constant over 50 passages in vitro [49,XX, -12, +der5, + 17, + mar1, + mar2]. Double minutes were a rare phenomenon and appeared only in a few metaphases. In situ hybridization showed that some of the HSR's consisted of amplified N-myc copies. The distribution of the N-myc copies according to in situ hybridization signals along the HSR's was compared with the data of Southern and Northern blotting analyses.

show abstract

“…Studies have demonstrated similar effectiveness of fractional CO 2 and Er:YAG lasers for improving texture, laxity, and dyschromia of the periorbital skin with improvement seen in approximately half of patients by six months [29] . One notable instance in which ablative lasers should be avoided, however, is in patients with Fitzpatrick skin types III-VI because of the greater risk of inducing postinflammatory dyspigmentation in this population [35,36] . Many providers may opt to avoid laser treatments in these patients altogether; however, certain fractional nonablative lasers, in particular long-pulsed diode, Er:glass, and Nd:YAG lasers, have been demonstrated to be both safe and effective [37][38][39] .…”

Section: Selecting the Appropriate Laser Treatmentmentioning

confidence: 99%

Laser Resurfacing for the Management of Periorbital Scarring

Pirakitikulr¹,

Martin²,

Wester³

2020

Plast Aesthet Res

View full text Add to dashboard Cite

Laser (light amplification by the stimulated emission of radiation) skin resurfacing is currently one of the most widely adopted technologies in facial rejuvenation. While most often used for aesthetic purposes, lasers also have applications in the management of scars. Since the introduction of the CO 2 laser for skin rejuvenation in the 1990s, the last three decades have seen significant growth in the number of laser devices available to the physician. More recently, promising alternatives to light-based resurfacing technologies have emerged that include radiofrequency and intense focused ultrasound. To help the physician navigate the most current laser technologies as they apply to periocular scars, this review discusses the available treatment modalities, pre-treatment assessment of periorbital scars, treatment selection, and reported outcomes and complications. The recommendations described herein are based on published literature and the authors' experience in an academic oculoplastics practice.

show abstract

Fragile sites and neuroblastoma: Fragile site at 1p13.1 and other points on lymphocyte chromosomes from patients and family members

Cited by 16 publications

References 15 publications

Strong Association of Chromosome 1p12 Loci with Thyroid Cancer Susceptibility

Strong Association of Chromosome 1p12 Loci with Thyroid Cancer Susceptibility

Cytogenetic and molecular characterization of a newly established neuroblastoma cell line LS

Laser Resurfacing for the Management of Periorbital Scarring

Contact Info

Product

Resources

About